Why does a skin appointment ask about the rest of my health?
Because psoriasis is not only skin deep. Guidance asks a clinician to look wider than the plaques, and some of those questions will sound unrelated at first. Evidence Evidence Evidence
Why this matters
- Reasonably supported
I read the National Psoriasis Foundation, which records psoriasis as an immune-mediated disease. An overactive immune system drives it, and it causes inflammation in the body. Raised plaques with scale are the visible sign. I read the joint AAD and NPF comorbidity guideline as well. It covers psoriasis alongside other health conditions, and it names psoriatic arthritis. It names heart and blood vessel disease. It names obesity, high blood pressure, raised blood fats and diabetes. It names inflammatory bowel disease and uveitis. It names depression and anxiety. NICE assessment covers the skin, the nails, high-impact sites, daily life and joint concerns.
Considerations
- Depends on you
A condition named in guidance is a link measured across groups. It is not a diagnosis. None of these records says which of them you have, or will get. Psoriasis also does not explain every new symptom, and a normal check today is not a promise about later.
Questions for your dermatologist
Which of these checks would you run, and which belong with my regular doctor?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Given my history, which of them matter most for me?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
My joints are stiff in the morning. Does that belong in this visit?
Yes. Say it out loud even if it seems unrelated to your skin. People I have heard from ask whether a stiff joint is psoriatic arthritis, and how they would know. I set the warning signs out in full on the guide linked below. Evidence Evidence Evidence
Why this matters
- Reasonably supported
I read the American Academy of Dermatology on the joint signs worth telling a dermatologist about. It records that psoriatic arthritis destroys the joints in some people. It records that early treatment helps prevent that. I checked the National Institute of Arthritis and Musculoskeletal and Skin Diseases too. It records that diagnosis uses clinical assessment, and that further evaluation may be needed. The comorbidity guideline asks clinicians to screen people with psoriasis for psoriatic arthritis.
Considerations
- Depends on you
A list of signs cannot diagnose you. The AAD page gives no share of people with psoriasis who go on to develop it. A stiff or sore joint has plenty of other causes. Age, an old injury and a new workout are three of them.
Questions for your dermatologist
My joints do ___ in the morning. Does that need a rheumatology referral?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Would you check my joints at every skin visit, or only when I raise it?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What do my weight, blood pressure and blood sugar have to do with it?
Guidance links psoriasis with heart risk and with weight, blood pressure, blood fats and blood sugar. So a review may look at numbers that seem to have nothing to do with skin. Evidence Evidence
Why this matters
- Reasonably supported
I read the comorbidity guideline, which asks clinicians to check heart risk factors in people with psoriasis. It names body weight, blood pressure, blood fats and blood sugar among those checks. It records heart and blood vessel disease among the conditions it covers. It records obesity, high blood pressure, raised blood fats and diabetes as well. I checked the American Academy of Dermatology, which records that quitting smoking lowers the risk of heart, blood vessel, liver and gum disease.
Considerations
- Depends on you
A link measured across groups does not set your own risk. The guideline reads no result and writes no personal plan. Which checks apply depends on your age, your history and where you are treated. The AAD page gives no percentage and no timeline for one person.
Questions for your dermatologist
Which of these numbers would you want checked, and how often for me?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What would you do with a result outside the usual range?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Could my gut or my eyes be part of this?
They can be. Guidance records inflammatory bowel disease and uveitis, an inflammation inside the eye, among the conditions it covers alongside psoriasis. Evidence Evidence
Why this matters
- Reasonably supported
The comorbidity guideline names inflammatory bowel disease among those conditions. It names uveitis as well. The American Academy of Dermatology records that quitting smoking lowers the risk of an autoimmune disease such as Crohn’s disease.
Considerations
- Depends on you
Gut symptoms and eye symptoms have many causes. Neither record counts how often either condition occurs in psoriasis. Neither one diagnoses you from a description. A red or painful eye needs an examination, and soon.
Questions for your dermatologist
My gut does ___. Is that worth investigating alongside my psoriasis?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Who should I call first if my eye turns red or painful?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Does mood get checked too?
Guidance asks clinicians to screen for depression, and two large studies are why. Low mood is common enough here that it belongs in the appointment, not beside it. Evidence Evidence Evidence Evidence
Why this matters
- Reasonably supported
I read a study that used a UK family-doctor database. It tracked more than 145,000 people with psoriasis. Noted depression was more common in that group, and so was noted anxiety. The rise in depression showed up in mild psoriasis, and it was larger in severe psoriasis. I compared it with a study across 13 European countries that screened skin-clinic patients for low mood and worry. Low mood was about twice as common as in a group with no skin problem. The National Institute of Arthritis and Musculoskeletal and Skin Diseases records that psoriasis carries mental-health risk. It names low self-esteem, anxiety and depression. The comorbidity guideline asks clinicians to screen for depression.
Considerations
- Depends on you
Neither study shows that psoriasis causes low mood. Neither judges one person. The UK study counts only what a doctor wrote down, so it misses what was never raised. The European study gives no figure for psoriasis alone. Feeling low is not a sign that you handled your skin badly.
Questions for your dermatologist
Can we do a mood check at this visit rather than a later one?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Who do I contact if my mood drops hard between appointments?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What should I bring, and does any of this change my treatment?
Bring a dated record and your medicine list. Your other health conditions can shape which treatment suits you, and that weighing belongs to your prescriber. Evidence Evidence Evidence Evidence
Why this matters
- Reasonably supported
I read the NICE assessment, which covers the skin, the nails, high-impact sites, daily life and joint concerns. The comorbidity guideline asks clinicians to screen for psoriatic arthritis, to check heart risk factors, and to screen for depression. The American Academy of Dermatology records that limiting alcohol is linked with treatment working better and lasting longer. It records a link with lower risk of fatty liver disease. It records a link with less liver damage from some psoriasis medicines. The AAD and NPF systemic guideline records methotrexate, apremilast, cyclosporine and acitretin among established systemic nonbiologic options.
Considerations
- Depends on you
The systemic guideline does not select, rank or prescribe an option for you. The comorbidity guideline writes no personal test plan. NICE is UK guidance, and it assesses nobody from a description. A dated record of your own flares, treatment changes and other conditions fills a gap no guideline can.
Questions for your dermatologist
I also have ___. Does that change which treatment you would pick for me?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What should I bring to the next review so we can decide faster?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence and update context
This optional layer shows the evidence boundary I reviewed as of 2026-09-19.
- What this evidence supports
- I read the National Psoriasis Foundation, which records psoriasis as an immune-mediated disease. An overactive immune system drives it, and it causes inflammation in the body. Raised plaques with scale are the visible sign. I read the joint AAD and NPF comorbidity guideline as well. It covers psoriasis alongside other health conditions, and it names psoriatic arthritis. It names heart and blood vessel disease. It names obesity, high blood pressure, raised blood fats and diabetes. It names inflammatory bowel disease and uveitis. It names depression and anxiety. NICE assessment covers the skin, the nails, high-impact sites, daily life and joint concerns.
- What it does not establish
- A condition named in guidance is a link measured across groups. It is not a diagnosis. None of these records says which of them you have, or will get. Psoriasis also does not explain every new symptom, and a normal check today is not a promise about later.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that poor sleep quality is a listed symptom of psoriasis. Also lists patches of thick, red, scaly skin that itch or burn, and dry, cracked skin that itches or bleeds. Supports that psoriasis carries risk for mental-health concerns including low self-esteem, anxiety, and depression. Supports that managing common triggers, such as stress and skin injuries, can help keep symptoms under control. Supports, by subtype, that guttate psoriasis outbreaks are often triggered by an upper respiratory infection such as strep throat. Also supports that pustular psoriasis symptoms can be triggered by medications, infections, stress, or certain chemicals. Also supports that erythrodermic psoriasis can be triggered by a bad sunburn or certain medications including corticosteroids. Also supports, by subtype, that inverse psoriasis appears as smooth patches of inflamed skin in skin folds. It names the armpits, the groin, and under the breasts as those folds. It records that rubbing and sweating can make inverse psoriasis worse.
What it does not support
Does not give a percentage of patients affected. Does not measure how much sleep is lost. Does not establish that treating the skin fixes the sleep problem for any one person. Its trigger information is organized by psoriasis subtype, not as one general list for plaque psoriasis specifically. It counts nothing for inverse psoriasis either. It gives no share of people affected in a fold or genital site, and it names no treatment for one.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports telling a dermatologist about a finger or toe that swells all the way along (a "sausage digit"). Also supports naming swollen, tender joints, and morning stiffness that lasts 30 to 45 minutes or longer and eases with movement. Also supports naming pitted or lifting nails, and low-back or heel pain, including swelling above the heel. Supports that for most people psoriatic arthritis develops years after psoriasis. Supports that psoriatic arthritis destroys the joints in some people, and that early treatment helps prevent this.
What it does not support
Does not give a percentage or fraction of people with psoriasis who go on to develop psoriatic arthritis. This page displays no separate revision date; the date recorded here matches the same AAD psoriatic-arthritis series’ treatment page, checked the same day. Does not diagnose psoriatic arthritis from a symptom list alone.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Archives of Dermatology (Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM)Observational study · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Funding and conflict notes were not checked beyond the published record. So the status here is set to not established.
What this source supports
Supports that one study used a UK family-doctor database. It tracked more than 145,000 people with psoriasis. It also tracked a much larger group with no psoriasis. Supports a higher rate of noted depression in the psoriasis group. Supports a higher rate of noted anxiety. Supports a higher rate of noted self-harm risk. Supports that the rise in depression showed up in mild psoriasis. Supports that the rise was larger in severe psoriasis.
What it does not support
Does not show that psoriasis causes any of this. Does not judge or predict one person. It counts only what a doctor wrote down. So it misses what was never raised in a visit. It covers one database and one span of years. It does not describe US care today.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of Investigative Dermatology (Dalgard FJ, Gieler U, Tomas-Aragones L)Observational study · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Funding and conflict notes were not checked beyond the published record. So the status here is set to not established.
What this source supports
Supports that skin-clinic patients in 13 European countries were screened. They were screened for low mood, for worry, and for thoughts of self-harm. A group with no skin problem was screened too. Supports that low mood was about twice as common in the patient group. Supports that worry was more common in the patient group. Supports that thoughts of self-harm were more common there too. Supports that psoriasis was one of the skin problems in the study.
What it does not support
Does not split psoriasis out from the other skin problems. Does not give a figure for psoriasis alone. It looked at people at one point in time. So it cannot show what came first. Does not judge or predict one person. It was run in Europe and does not describe US care today.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that quitting smoking is linked to fewer flares and less palmoplantar psoriasis. Supports that it is linked to more remissions. Supports that quitting also lowers the risk of heart, blood vessel, liver, and gum disease. Supports that it lowers the risk of an autoimmune disease like Crohn's disease. Supports the caution that a nicotine patch can make psoriasis flare, and to ask a dermatologist before using one. Supports that limiting alcohol is linked to treatment working better and lasting longer. Supports that it is linked to a lower risk of psoriatic arthritis in women. Supports that it is linked to a lower risk of fatty liver disease and liver damage from some psoriasis medications. Supports a named threshold: more than 2 drinks a day for men, or more than 1 for women. Supports that above that threshold, treatment may stop working, work less well, or lead to fewer remissions.
What it does not support
Does not give a percentage or timeline for one person. The page shows no visible byline or update date. The site copyright year, 2026, is used here.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the American Academy of Dermatology (Elmets CA, Leonardi CL, Davis DMR, et al.)Guideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The guideline reports author relationships with industry. It is expert guidance, not independent proof for one person.
What this source supports
Supports that this guideline covers psoriasis alongside other health conditions. Supports naming psoriatic arthritis as one of them. Supports naming heart and blood vessel disease. Supports naming obesity, high blood pressure, raised blood fats and diabetes. Supports naming inflammatory bowel disease. Supports naming uveitis, an inflammation inside the eye. Supports naming depression and anxiety. Supports that it asks clinicians to screen people with psoriasis for psoriatic arthritis. Supports that it asks them to check heart risk factors. Supports naming body weight, blood pressure, blood fats and blood sugar among those checks. Supports that it asks them to screen for depression.
What it does not support
Does not diagnose a reader. Does not say which linked condition one person will get. Does not read a test result or set a personal plan. Its authors report industry relationships. It is US guidance. It does not set practice in another country.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The organization publishes patient education, but the editorial and funding independence of this page was not separately reviewed.
What this source supports
Supports that psoriasis is an immune-mediated disease. It causes inflammation in the body. Raised plaques and scale on the skin are the visible sign. Supports that an overactive immune system speeds up skin-cell growth. Skin cells normally take about a month to grow and shed. With psoriasis they do so in three or four days. Supports that psoriasis is a chronic, long-term disease with no cure.
What it does not support
Does not predict whether one person will clear, stay the same, or flare. Does not give a share of people who reach a period with little or no psoriasis, or how long such a period lasts. The page shows no visible byline or update date. The site copyright year, 2026, is used here.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute for Health and Care ExcellenceGuideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports psoriasis assessment across skin, nails, high-impact sites, life impact and joint concerns; same-day specialist assessment for generalised pustular psoriasis or erythroderma; and a treatment map that includes topical, phototherapy and systemic options.
What it does not support
It is UK guidance and does not diagnose a reader, create a US treatment sequence, determine personal urgency from a description, or establish current US labeling or coverage.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The guideline reports author relationships; it is not independent comparative proof for an individual choice.
What this source supports
Supports that methotrexate, apremilast, cyclosporine and acitretin are established systemic nonbiologic options considered in psoriasis care.
What it does not support
It does not select, rank or prescribe an option for an individual reader.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports bringing joint, tendon, swelling, stiffness and nail concerns to a clinician because diagnosis uses clinical assessment and may require further evaluation.
What it does not support
It is not an online screening result and cannot diagnose psoriatic arthritis from a checklist.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.